Mentoring in drug abuse and dual diagnosis research

药物滥用和双重诊断研究的指导

• 批准号: 8897314
• 负责人: Roger D. Weiss
• 金额: $ 17.7万
• 依托单位: MCLEAN HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-10 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8897314
• 关键词: Alcohol abuse; Applications Grants; Area; Award; Bipolar Disorder; Brain imaging; Clinical; Clinical Research; Clinical Sciences; Clinical Trials Network; Clinical and Translational Science Awards; Communities; Data; Data Set; Development Plans; Diagnosis; Disease; Doctor of Medicine; Drug abuse; Foundations; Funding; Genetic; Goals; Group Meetings; Group Therapy; Hospitals; Individual; K-Series Research Career Programs; Learning; Massachusetts; Mentors; Mentorship; Mid-Career Clinical Scientist Award (K24); Mood Disorders; National Institute of Drug Abuse; Opiate Addiction; Pain; Pain Clinics; Paper; Patients; Pharmaceutical Preparations; Psychiatry; Public Health; Publications; Randomized Controlled Trials; Research; Research Personnel; Site; Substance Addiction; Time; Training; Translational Research; United States National Institutes of Health; Universities; Work; Writing; career; career development; chronic pain; clinical practice; design; dual diagnosis; effective therapy; follow-up; interest; medical schools; next generation; opioid misuse; patient oriented research; patient population; prescription opioid; professor; programs; research study; responsible research conduct; role model; skills

DESCRIPTION (provided by applicant): The primary goals of this K24 competing renewal application are to enable Roger Weiss, M.D., to 1) continue to conduct and extend his patient-oriented research (POR) with drug dependent patients, particularly those with co-occurring disorders; and 2) provide intensive and high-quality mentorship to early-career investigators in POR. A K24 renewal will continue to give Dr. Weiss protected time for research and mentoring that would otherwise be spent on clinical and administrative duties. Dr. Weiss, Professor of Psychiatry at Harvard Medical School and Chief of the Division of Alcohol and Drug Abuse at McLean Hospital, Belmont, Massachusetts, has conducted POR since 1980, emphasizing studies that 1) integrate different treatment approaches, and 2) influence clinical practice. Since receiving a K24 award in September 2007, Dr. Weiss has accomplished the major goals of his original application. He has mentored 35 junior investigators, including 17 with K awards. He has authored 72 publications, including 34 publications with a mentee as first author. He successfully completed a randomized controlled trial of a "community-friendly" version of Integrated Group Therapy that he developed for patients with bipolar disorder and substance dependence, and successfully led a multi-site study of prescription opioid dependence treatment in the NIDA Clinical Trials Network (CTN). Dr. Weiss' research plan for this renewal application includes continued work as a Node PI in the NIDA CTN, in which he is leading a long-term follow-up study of patients with prescription opioid dependence. He will also serve as Co-Investigator or consultant on several studies with mentees as PI. Further, he plans to submit proposals to 1) expand the scope of Integrated Group Therapy to include all mood disorders, and 2) study treatment approaches for pain clinic patients who misuse opioids. Dr. Weiss' mentoring plan includes training his mentees in 1) clinical aspects of drug abuse; 2) designing and implementing drug abuse research studies; 3) preparing scientific papers and presentations; 4) writing successful grant applications; and 5) responsible conduct of research. He will accomplish this with a combination of individual and group meetings; collaborative mentoring; role modeling; and integrating mentoring with the Harvard Clinical and Translational Science Award (CTSA) Consortium. Dr. Weiss' career development plan involves learning more about treatment and clinical research with patients with severe pain and opioid dependence in a pain clinic; longitudinal data analytic strategies; and genetics. These activities will simultaneously enhance Dr. Weiss' research and his mentoring skills. The public health importance of this application is related to the need to develop new and effective treatments for drug dependent and dually diagnosed patients, and the need to train the next generation of investigators to develop the skills they require to effectively conduct POR with this patient population.

描述（由申请人提供）：此 K24 竞争性续展申请的主要目标是使医学博士 Roger Weiss 能够 1) 继续开展和扩展其针对药物依赖患者的以患者为导向的研究 (POR)，特别是那些患有共存疾病的患者发生疾病； 2) 为 POR 的早期职业研究人员提供密集和高质量的指导。 K24 续约将继续为 Weiss 博士提供受保护的研究和指导时间，否则这些时间将用于临床和行政职责。 Weiss 博士是哈佛医学院精神病学教授，也是马萨诸塞州贝尔蒙特麦克莱恩医院酒精和药物滥用科主任，自 1980 年以来一直进行 POR，强调研究 1) 整合不同的治疗方法，2) 影响临床实践。自从 Weiss 博士于 2007 年 9 月获得 K24 奖，他已经完成了最初申请的主要目标。他指导了 35 名初级研究员，其中 17 名获得了 K 奖。他撰写了 72 篇出版物，其中 34 篇出版物由受训者作为第一作者。他成功完成了针对双相情感障碍和物质依赖患者开发的“社区友好”版综合团体治疗的随机对照试验，并成功领导了 NIDA 临床试验网络中处方阿片类药物依赖治疗的多中心研究（CTN）。 Weiss 博士对此续订申请的研究计划包括继续担任 NIDA CTN 的节点 PI，其中他正在领导一项针对处方阿片类药物依赖患者的长期随访研究。他还将担任多项研究的联合研究员或顾问，学员将担任 PI。此外，他计划提交提案：1）扩大综合团体治疗的范围，以包括所有情绪障碍；2）研究针对滥用阿片类药物的疼痛诊所患者的治疗方法。 Weiss 博士的指导计划包括在 1) 药物滥用的临床方面对他的学员进行培训； 2) 设计和实施药物滥用研究； 3）准备科学论文和演示文稿； 4）撰写成功的资助申请； 5) 负责任地进行研究。他将通过个人会议和小组会议相结合的方式来实现这一目标；协作指导；角色建模；并将指导与哈佛临床和转化科学奖 (CTSA) 联盟整合起来。 Weiss 博士的职业发展计划包括更多地了解疼痛诊所中患有严重疼痛和阿片类药物依赖的患者的治疗和临床研究；纵向数据分析策略；和遗传学。这些活动将同时增强韦斯博士的研究和指导技能。该应用对公共卫生的重要性涉及到为药物依赖和双重诊断患者开发新的有效治疗方法的需要，以及培训下一代研究人员以培养他们对该患者群体进行有效进行 POR 所需的技能的需要。